One year in review
Clinical manifestations, imaging and treatment of Sjögren’s disease: one year in review 2024
F. Tromby1, V. Manfrè2, L.G. Chatzis3, S. Arends4, A.G. Tzioufas5, H. Bootsma6, L. Quartuccio7, E. Bartoloni8
- Rheumatology Unit, Department of Medicine and Surgery, University of Perugia, Italy.
- Division of Rheumatology, Academic Hospital Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy.
- Department of Pathophysiology, School of Medicine University of Athens; and Laboratory of Autoimmunity, Center of Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation, Academy of Athens, Greece.
- Department of Rheumatology and Clinical Immunology, University Medical Centre Groningen, The Netherlands.
- Department of Pathophysiology, School of Medicine University of Athens; and Laboratory of Autoimmunity, Center of Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation, Academy of Athens, Greece.
- Department of Rheumatology and Clinical Immunology, University Medical Centre Groningen, The Netherlands.
- Division of Rheumatology, Academic Hospital Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy.
- Rheumatology Unit, Department of Medicine and Surgery, University of Perugia, Italy. elena.bartolonibocci@unipg.it
CER18190
2024 Vol.42, N°12
PI 2322, PF 2335
One year in review
Free to view
(click on article PDF icon to read the article)
PMID: 39656599 [PubMed]
Received: 27/09/2024
Accepted : 08/11/2024
In Press: 06/12/2024
Published: 19/12/2024
Abstract
Sjögren’s disease is a systemic autoimmune disorder characterised by hyperactivation of B-cells and cytokine production. The condition may evolve from an asymptomatic, indolent course, with glandular involvement, to several extra-glandular systemic manifestations up to lymphoma development. Recent efforts have been undertaken to identify patient phenotypes at risk of developing specific extraglandular manifestations in order to improve patient management. A more detailed understanding and characterisation of pathogenetic mechanisms, operating during the course of the disease, may facilitate earlier diagnosis, enable subphenotyping of patients and suggest novel therapeutic modalities to address the unmet needs of the disease in the upcoming years. In this review, following the others of this series, we will summarise the most recent literature on Sjögren’s disease pathogenesis and clinical features focusing in particular on new insights into Sjögren’s disease molecular stratification and therapeutic advances in the era of precision medicine.
